Joanne E Mortimer
City Of Hope/beckman Research Institute
Project start date: 1988-01-01
Project end date: 2015-12-31
Sponsored Links Excellgen http://Excellgen.com
City Of Hope Southwest Oncology Group Clinical Trials
Joanne E Mortimer, Professor Of Medicine
City Of Hope/beckman Research Institute
Grant 5U10CA046368-22 from National Cancer Institute IRG: NCI
Abstract: The overall objective of this proposal is to support the participation of the City of Hope National Medical Center (COH) in the investigational clinical trials of the Southwest Oncology Group (SWOG). The COH, an NCI-designated Comprehensive Cancer Center, has supplied strong leadership for the clinical research activities of SWOG during the past six years. SWOG members at COH have provided substantial scientific input into the development of new therapeutic programs for hematological malignancies as well as all aspects of high-dose chemotherapy with stem cell support for the group; in addition, expertise in oncologic pharmacology, cytogenetics, immunotherapy, genitourinary cancers, and gynecologic pathology and tumor biology will continue to support pilot protocol development for SWOG as well as participation in group-wide Phase II and Phase III studies. SWOG members from COH also contribute substantially to research activities in oncologic surgery and cancer prevention. COH physicians and scientists have increased their leadership activities within SWOG during the current funding cycle, adding the chairmanships of the Genitourinary Committee´s Testis Cancer Subcommittee and the newly formed Early Therapeutics Committee to continuing service as chairs of the Bone Marrow and Stem Cell Transplantation Committee, and the Gynecology Committee´s Pathology and Tumor Biology Subcommittees. In addition to these leadership positions, the scientific productivity of COH investigators within SWOG has continued to increase. At the time of the last competitive review of COH´s participation in SWOG, 9 COH investigators had published 18 papers and 14 s reporting SWOG clinical investigations; over the past six years, 12 COH investigators have published 31 papers and 28 s describing SWOG research in high-quality, peer-reviewed publications. Based on the presence of a dedicated, multidisciplinary team of physicians in Pathology, Surgical Oncology, Radiation Oncology, and Cancer Control as well as Medical Oncology, Experimental Therapeutics, and Hematology who are committed to the investigations pursued by SWOG, substantive scientific leadership of and patient accrual to SWOG clinical trials by the COH can be predicted to continue over the coming funding cycle. Furthermore, participation by the COH in the innovative treatment concepts devised by SWOG will broaden the availability of investigational cancer care in the greater Southern California region
Keywords: combination cancer therapy, combination chemotherapy, human therapy evaluation, neoplasm /cancer chemotherapy, neoplasm /cancer immunotherapy, neoplasm /cancer radiation therapy, neoplasm /cancer surgery, oncology antineoplastic, bone marrow transplantation, brain neoplasm, breast neoplasm, cancer information system, cancer prevention, cancer registry /resource, cis platinum compound, clinical trial, cooperative study, cyclophosphamide, doxorubicin, drug resistance, female reproductive system neoplasm, fludarabine, gastrointestinal neoplasm, head /neck neoplasm, hormone therapy, ifosfamide, leukemia, lung neoplasm, lymphoma, meeting /conference /symposium, melanoma, multiple myeloma, neoplasm /cancer diagnosis, neoplasm /cancer epidemiology, neoplasm /cancer genetics, paclitaxel, pancreas neoplasm, prostate neoplasm, sarcoma, tamoxifen, urinary tract neoplasm clinical research, human subject
Project start date: 1988-01-01
Project end date: 2009-12-31
Grants awarded to Joanne E Mortimer
CITY OF HOPE SOUTHWEST ONCOLOGY GROUP CLINICAL TRIALS
Joanne E Mortimer, Vice Chair, Medical Oncology
City Of Hope/beckman Research Institute, 1500 East Duarte Road, Modular, #103, Duarte, Ca 91010-3000
Grant 2U10CA046368-23 from National Cancer Institute
Abstract: This renewal application requests funding for the continuation of the Southwest Oncology Group Clinical Trials Cooperative Grant at City of Hope (COH) for years 23-28. The COH faculty has a longstanding commitment to the Southwest Oncology Group as demonstrated by their leadership in the group, involvement in protocol development, meeting attendance, and enrollment of patients on SWOG studies. Dr. Steven Forman has chaired the BMT Committee since 1993 and pilot studies first tested at City of Hope have been incorporated into treatment arms on SWOG trials. Many of our faculty are Principal Investigators on SWOG trials and our annual enrollment to SWOG studies exceeds 100 patients per year. Our faculty involvement spans many disciplines including Medical Oncology, General Surgical Oncology, Urology, Pathology, Pharmacy and Pharmacology who serve on critical committees and enroll patients on clinical trials. SWOG members from COH also contribute substantially to research activities in oncologic surgery and cancer prevention. Substantive scientific patient accrual to SWOG clinical trials by the COH can be predicted to continue over the coming funding cycle. Our faculty have authored numerous publications. Clinical research through the Southwest Oncology Group continues to be an important part of the COH research portfolio. Recognizing the importance of SWOG to the institution, City of Hope supports the regulatory, data collection, and quality assurance infrastructure that is not entirely supported by the current grant. We anticipate that our participation in SWOG will continue to grow as our institution expands both on the main Duarte campus and with our burgeoning affiliate program. RELEVANCE City of Hope recognizes the improved quality of patient care that is associated with participation in clinical trials. The institution is committed to enrolling our diverse population of patients on SWOG clinical trials. PRINCIPAL INVESTIGATOR Dr. Mortimer is well qualified to lead this effort at COH. Although she has been at COH only since 2007, her background in the leadership of oncology units at other institutions and in clinical research is extensive. She is a member of the Breast and Special Populations committees. PROTECTION OF HUMAN SUBJECTS (Resume) ACCEPTABLE No concerns are evident. INCLUSION OF WOMEN PLAN (Resume) ACCEPTABLE No concerns are evident. INCLUSION OF MINORITIES PLAN (Resume) ACCEPTABLE No concerns are evident. The City of Hope investigators have been successful in recruiting Hispanics (10%) and Asian Pacific Islanders (14%) into SWOG clinical trials. INCLUSION OF CHILDREN PLAN (Resume) ACCEPTABLE Enrolled subjects are generally 18 years of age or older. OVERALL RECOMMENDATION This application is rated 21 and recommended for six years of funding
Keywords: 18 year old; Arm; Asians; Breast; Cancer, Oncology; Cities; Clinical Research; Clinical Study; Clinical Trials; Clinical Trials, Unspecified; Commit; Data Collection; Discipline; Enrollment; Faculty; Funding; Grant; Heterogeneity, Population; Hispanic Populations; Hispanics; Hispanics or Latinos; Infrastructure; Institution; Investigators; Latino Population; Lead; Leadership; Medical Oncology; NIH RFA; Pacific Island Americans; Pacific Islander; Pacific Islander American; Pathology; Patient Care; Patient Care Delivery; Patients; Pb element; Pharmacies; Pharmacology; Pharmacy facility; Pilot Projects; Population Heterogeneity; Principal Investigator; Programs (PT); Programs [Publication Type]; Publications; Qualifying; Recommendation; Recruitment Activity; Request for Applications; Research; Research Activity; Research Infrastructure; Research Personnel; Researchers; SWOG; Scientific Publication; Southwest Oncology Group; Spanish Origin; Special Population; Surgical Oncology; Testing; Upper arm; Urology; cancer prevention; clinical investigation; diverse populations; eighteen year old; enroll; heavy metal Pb; heavy metal lead; heterogeneous population; hispanic community; improved; meetings; member; named group; oncologic surgery; oncology; oriental; pilot study; programs; protocol development; quality assurance; recruit
Project start date: 1988-01-01
Project end date: 2015-12-31
Budget start date: 7-APR-2010
Budget end date: 31-DEC-2010
2U10CA046368-23 (2010): $431902
CITY OF HOPE CLINICAL ONCOLOGY CAREER RESEARCH DEVELOPMENT PROGRAM
Joanne E Mortimer
City Of Hope/beckman Research Institute, 1500 East Duarte Road, Modular, #103, Duarte, Ca 91010-3000
Grant 5K12CA001727-17 from National Cancer Institute
Abstract: The objective of the City of Hope (COH) Clinical Oncology Research Career Development Program is to develop a new generation of clinical oncologic investigators capable of translating basic advances in cancer biology into novel strategies for the diagnosis, therapy, and prevention of malignant disease. This multi-disciplinary effort will be available to outstanding surgeons, radiation oncologists, pathologists, pediatricians, and internists who have completed their fellowship training in oncology, who are in the early stages of their career, and who are appropriate for appointment to the faculty of the Cancer Center. COH has pursued as one of its central goals, the enhancement of interactive basic and clinical research at the cutting edge of molecular genetics, virology and gene therapy, immunology and immunotherapy, bone marrow transplantation and stem cell biology, and experimental therapeutics. Since the inception of the COH CORCD Program in 1992, trainee enrollment has included surgical oncologists (including a urologic surgical oncologist and a neurosurgical oncologist), medical oncologists and hematologic malignancies and bone marrow transplant oncologists. Nine of the ten graduates of the Program have full-time academic positions at a NCI-designated comprehensive cancer center; the tenth is Director of Clinical Research for a pharmaceutical company. In this proposal, we describe a four-year curriculum within a 75% protected time appointment that involves both didactic and practical experience in biostatistics, clinical investigation, basic science and laboratory research for training clinical investigators at the junior faculty level. During the first year, the comprehensive core curriculum involves Methodology in Clinical Investigation, Scientific Writing, Biomedical Tools and Resources, Research Seminars, and Journal Club. Paul Calabresi Scholars will also initiate their supervised clinical research by choosing clinical and laboratory mentors. Scholars will be supervised by clinical and laboratory mentors throughout their tenure. In Year 2 and beyond, trainees will take courses in Clinical Pharmacology and three electives. Trainees will continue their experience in Research Seminars, and Journal Club, as well as the expansion of their specific supervised clinical research. The activities of the trainees will be carefully assessed during all aspects of the training period with quarterly presentations of their research progress, and meetings with Dr. Figlin, the Program Director. Requirements for satisfactory completion of the CORCD Program include the publication of a report of the trainee´s clinical and/or laboratory research in a peer-reviewed journal, completion of a clinical research protocol which will be IRB approved for patient accrual, and a grant application detailing an appropriate clinical and/or laboratory study that is suitable for submission to the NIH. RELEVANCE This proposal describes a program that is aimed at developing a new generation of clinical oncologic investigators capable of translating laboratory science to the clinic. It is available to those investigators in the early stages of their career. The program combines an excellent curriculum and research experience to increase the number of physician-scientists who will become leaders for advancing cancer research
Keywords: Address; Advanced Cancer; Advanced Malignant Neoplasm; Applications Grants; Appointment; Area; Award; Basic Research; Basic Science; Biometrics; Biometry; Biometry and Biostatistics; Biostatistics; Bone Marrow Transplant; Bone Marrow Transplantation; Budgets; Businesses; Cancer Biology; Cancer Center; Cancer, Oncology; Career Development Awards; Career Development Awards and Programs; Career Development Programs K-Series; Certification; Cities; Clinic; Clinical; Clinical Investigator; Clinical Oncology; Clinical Oncology Research Career Development Program; Clinical Oncology Research Career Development Program (K12); Clinical Oncology Supplement (K12); Clinical Pharmacology; Clinical Research; Clinical Research Protocols; Clinical Study; Clinical Trials; Clinical Trials, Phase III; Clinical Trials, Unspecified; Code; Coding System; Coloring Agents; Comprehensive Cancer Center; Contracting Opportunities; Contracts; Curriculum; Diagnosis; Direct Costs; Disease; Disorder; Doctor of Medicine; Dyes; Economically Deprived; Economically Deprived Population; Educational Curriculum; Enrollment; Ethics Committees, Research; Face; Faculty; Fellowship; Gene Transfer Clinical; Gene Transfer Procedure; Gene-Tx; Generations; Genetic Intervention; Goals; Grafting, Bone Marrow; Grant; Grant Proposals; Grants, Applications; Hematologic Cancer; Hematologic Malignancies; Hematologic Neoplasms; Hematological Malignancies; Hematological Neoplasms; Hematological Tumor; Hematopoietic Cancer; Human; Human, General; IRBs; ITX; Immunologically Directed Therapy; Immunology; Immunology (Including BRMP); Immunology (NCI Program); Immunotherapy; Institutional Clinical Oncology Research Career Development Program (K12); Institutional Review Boards; Instruction; Internist; Intervention, Genetic; Investigators; Journals; K-Awards; K-Series Research Career Programs; K12; K12 Award; Knowledge; Laboratories; Laboratory Research; Laboratory Study; Last Name; M.D.; Magazine; Malignant; Malignant - descriptor; Malignant Hematologic Neoplasm; Man (Taxonomy); Man, Modern; Marrow Transplantation; Medical Oncologist; Medical Oncology; Mentors; Method LOINC Axis 6; Methodology; Molecular Biology, Gene Therapy; Molecular Genetic; Molecular Genetics; NIH; NIH RFA; Names; National Institutes of Health; National Institutes of Health (U.S.); Oncologic Surgeon; Oncologist; Pathologist; Patients; Pharmaceutical Agent; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Phase 3 Clinical Trials; Phase III Clinical Trials; Phone; Physicians; Position; Positioning Attribute; Prevention therapy; Principal Investigator; Programs (PT); Programs [Publication Type]; Public Health Service; Public Health Service (U.S.); Publications; Radiation Oncologist; Reporting; Request for Applications; Research; Research Career Program; Research Career Programs, K-Series; Research Ethics Committees; Research Institute; Research Personnel; Research Resources; Research Training; Researchers; Resources; SECTM1; SECTM1 gene; ST-ADDR; Science; Science of Virology; Scientific Publication; Scientist; Services; Staging; Street Address; Surgeon; Surgical Oncologist; Telephone; Therapeutic; Therapy, DNA; Time; Training; Translating; Translatings; USPHS; United States National Institutes of Health; United States Public Health Service; Virology; Woman; Writing; anticancer research; cancer research; career; clinical investigation; cost; disease/disorder; enroll; experience; facial; gene therapy; genetic therapy; immune therapy; language translation; meetings; new approaches; novel approaches; novel strategies; novel strategy; oncology; pediatrician; peer; phase 3 study; phase 3 trial; phase III trial; professor; programs; protocol, phase III; response; statistics/biometry; stem cell biology; study, phase III; tool; urologic; urological; virology
Project start date: 1992-09-09
Project end date: 2014-08-31
Budget start date: 1-SEP-2010
Budget end date: 31-AUG-2011
PFA/PA: PAR-06-449
5K12CA001727-17 (2010): $740319